Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Kamuju Suryahari & Immadi Sreevallika

Clinical Trials, India

Title: Non-interventional, retrospective and anonymized data base study on breast tumors for markers predictive of risk of recurrence

Biography

Biography: Kamuju Suryahari & Immadi Sreevallika

Abstract

Non-interventional, retrospective & anonymized data base study on  breast tumors for markers predictive of risk of recurrence: This is a non-interventional, anonym zed and retrospective research study. It does not involve enrollment of patients/administration of drugs. The study uses left over FEPE tumor blocks remaining after routine diagnosis for the patient is over. IHC/RTPCR based tests will be done on these blocks. Each patient will be de-identified with a unique code, by the hospital. No contact between patient and researcher at any point of time, thus study will have no side effects on the health of the patient. Main aim the study To carry out a non -intervenaial, retrospective & anonymized  study on 2000 breast cancer tumors to assess biomarkers for :

i) Prediction of risk of cancer recurrence

ii) Usefulness of chemo/radio therapy

iii) Overall effective cancer treatment planning.

Benefits :

1) Patients will avoid excessive therapy/ side effects & enjoy improved quality of life & save resources.

2) Medical oncologists can prescribe most effective therapy and targeted drugs .

Cancer and Recurrence:

*ASCO report: 1M new cancer cases in India per year. 12 Million Breast cancer survivors in US. In India 2.4M  breast cancer cases.

*Cancer recurrence is the most feared aspect of cancer as it is responsible for the Morbidity and mortality associated with the disease.

*Current means to predict risk of recurrence are limited. Treatment can be planned optimally if recurrence information is available.

Mission: To develop novel diagnostic tests for prediction of risk of recurrence for ALL cancers, first focus on breast cancer.

Clinical Trials Company Established in Year 2015. Currently the company is working with leading Medical Oncologists in India. Involving the Clinical Trials as well as the Molecular testing and Bio Marker Investigations. Most of the Trials involved in Medical Oncology related areas such as (Breast Cancer, Metastatic Colorectal Cancer, Head & Neck Cancer and other Lymphomas.